I'll answer 2 of your questions.
"I have seen nothing that prohibits Oncologie to assign all their rights to a third party (for a fee) to do the developing or do a joint venture with a BP"
Correct, the answer to this is in the "ASSET ASSIGNMENT AND PURCHASE AGREEMENT".
We need a SEC document on that.
"So did they get Bio markers and Exsomes? For what it is worth did they get Cotara?"
From the PR with more probably in the above agreement.
" In addition to bavituximab, the deal includes Avid’s other PS-targeting antibodies, including betabodies, as well as certain other assets and licenses useful and/or necessary for the potential commercialization of bavituximab."
You just asked this again of JDM which I thought I just answered but .......
"Like to see if their are ongoing requirements for minimum development"
I think you need to re-read the PR. Some of the questions you are asking are there.
IMO
News 
Market Data 
Discover 
AI
